Novartis files Tasigna, Aclasta ahead of schedule
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis announces the submission of NDAs for the oncologic Tasigna (nilotinib) and osteoporosis therapy Aclasta (zoledronic acid infusion) during its annual pipeline update Nov. 28 in London. The company had been predicting 2007 filings for both applications (1Pharmaceutical Approvals Monthly May 2006, p. 3). The Tasigna application, filed in both the U.S. and Europe, seeks an indication for treatment of chronic myeloid leukemia; Novartis also announced a global nilotinib expanded access program called ENACT that will be available to eligible patients in all phases of Philadelphia chromosome-positive CML who are resistant to or intolerant of Novartis' Gleevec (imatinib). Novartis seeks to differentiate Aclasta in the crowded osteoporosis market with its once-yearly administration and complete range of claims for "vertebral, both clinical and non-clinical vertebral diagnosed by x-ray, as well as hip and non-vertebral sites," Global Pharma Development Head James Shannon told investors...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.